What is the most recent earnings date for LCTX stock?
LINEAGE CELL THERAPEUTICS IN (LCTX) last reported earnings on 3/5/2026.
LINEAGE CELL THERAPEUTICS IN (LCTX) Earnings History & Surprises
NYSEARCA:LCTX • US53566P1093
Current stock price
1.585 USD
-0.02 (-0.94%)
Last:
LCTX Earnings overview
Past quarterly earnings results for LINEAGE CELL THERAPEUTICS IN (LCTX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.01
- Revenue Estimate
- 4.813M
Last Reported
Most Recent- Release Date
- Mar 5, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.00
- EPS Surprise
- 100.00%
- Revenue Surprise
- 151.35%
Beat Rate
Last 8 Quarters 69%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.00 | -0.05 | 100.00% | 100.00% | 6.608M | 2.629M | 151.35% | 130.40% |
| Q3 2025 | -0.13 | -0.03 | -395.73% | -550.00% | 3.681M | 2.346M | 56.91% | -2.59% |
| Q2 2025 | -0.07 | -0.03 | -152.86% | -133.33% | 2.765M | 1.502M | 84.09% | 96.38% |
| Q1 2025 | -0.02 | -0.03 | 21.57% | 50.00% | 1.502M | 1.904M | -21.11% | 4.02% |
| Q4 2024 | -0.01 | -0.01 | -14.40% | 66.67% | 2.868M | 1.654M | 73.40% | 37.36% |
| Q3 2024 | -0.02 | -0.04 | 54.25% | 50.00% | 3.779M | 1.054M | 258.54% | 203.29% |
| Q2 2024 | -0.03 | -0.05 | 36.06% | - | 1.408M | 988.635K | 42.42% | -56.34% |
| Q1 2024 | -0.04 | -0.04 | -2.31% | -33.33% | 1.444M | 1.387M | 4.11% | -39.48% |
| Q4 2023 | -0.03 | -0.04 | 31.38% | - | 2.088M | 1.336M | 56.29% | 8.75% |
| Q3 2023 | -0.04 | -0.04 | 8.50% | - | 1.246M | 2.646M | -52.91% | -58.47% |
| Q2 2023 | -0.03 | -0.05 | 33.59% | 25.00% | 3.225M | 2.241M | 43.91% | -29.12% |
| Q1 2023 | -0.03 | -0.04 | 23.27% | 25.00% | 2.386M | 2.049M | 16.45% | -54.47% |
| Q4 2022 | -0.03 | -0.04 | 20.81% | 82.35% | 1.92M | 2.617M | -26.63% | 64.10% |
| Q3 2022 | -0.04 | -0.04 | -12.04% | 20.00% | 3M | 3.975M | -24.53% | 32.16% |
| Q2 2022 | -0.04 | -0.04 | 8.50% | -33.33% | 4.55M | 3.758M | 21.08% | 792.16% |
| Q1 2022 | -0.04 | -0.03 | -15.34% | -300.00% | 5.24M | 7.47M | -29.85% | 1,243.59% |
| Q4 2021 | -0.17 | -0.05 | -257.12% | -1,800.00% | 1.17M | 856.8K | 36.55% | 225.00% |
| Q3 2021 | -0.05 | -0.05 | -2.12% | - | 2.27M | 521.22K | 335.52% | 298.25% |
| Q2 2021 | -0.03 | -0.04 | 19.79% | 25.00% | 510K | 418.2K | 21.95% | 30.77% |
| Q1 2021 | -0.01 | -0.04 | 71.99% | 83.33% | 390K | 357K | 9.24% | -23.53% |
| Q4 2020 | 0.01 | -0.05 | 121.31% | - | 360K | 939.93K | -61.70% | - |
| Q3 2020 | -0.05 | -0.05 | -8.93% | - | 570K | 438.6K | 29.96% | - |
| Q2 2020 | -0.04 | -0.04 | 1.96% | - | 390K | 568.905K | -31.45% | - |
| Q1 2020 | -0.06 | -0.05 | -22.55% | - | 510K | 656.88K | -22.36% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-106.76%
Max EPS beat (4)
100.00%
Min EPS beat (4)
-395.73%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
67.81%
Max Revenue beat (4)
151.35%
Min Revenue beat (4)
-21.11%
Analysis
In the last 4 quarters, LCTX has beaten EPS estimates in 2 out of 4 releases
LCTX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, LCTX reported -106.8% below the EPS estimates on average.
In the last 4 quarters, LCTX has beaten the revenue estimates by 67.8% on average.
Related analysis
LINEAGE CELL THERAPEUTICS IN / LCTX Earnings FAQ
Did LCTX stock beat earnings estimates in the most recent quarter?
LINEAGE CELL THERAPEUTICS IN (LCTX) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does LCTX stock beat earnings estimates?
In the last 4 quarters, LINEAGE CELL THERAPEUTICS IN (LCTX) has beaten EPS estimates in 2 out of 4 releases.